BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/20/2025 3:37:30 AM | Browse: 137 | Download: 521
 |
Received |
|
2024-12-31 04:08 |
|
Peer-Review Started |
|
2024-12-31 04:08 |
|
First Decision by Editorial Office Director |
|
2025-02-19 07:31 |
|
Return for Revision |
|
2025-02-19 07:31 |
|
Revised |
|
2025-02-25 03:17 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-03-25 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-03-25 07:33 |
|
Articles in Press |
|
2025-03-25 07:33 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-04-28 02:43 |
|
Publish the Manuscript Online |
|
2025-05-20 03:37 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Treatment strategies targeting the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway against triple-negative breast cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Xiao Ni, Jia-Ju Xu, Yu Pang and Jia-Ju Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Scientific Research Fund of Tai’an Science and Technology Agency |
2019NS180 |
|
| Corresponding Author |
Jia-Ju Xu, MD, Department of Medical Oncology, Tai’an Central Hospital Affiliated to Qingdao University, No. 29 Longtan Road, Taishan District, Tai’an 271000, Shandong Province, China. jiajuxu1101@163.com |
| Key Words |
Triple negative breast cancer; Phosphoinositide 3-kinase; Protein kinase B; Mechanistic target of rapamycin; Biomarkers; Natural products; Inhibitors; Therapy |
| Core Tip |
Triple-negative breast cancer is an aggressive subtype of breast cancer with a poor prognosis. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway regulates cell proliferation, growth, metabolism, and survival. This review analyzes biomarkers associated with this pathway in triple-negative breast cancer, including proteins, mRNA, non-coding RNA, and transcription factors. Furthermore, it systematically examines key natural products targeting the pathway, such as flavonoids, terpenoids, and alkaloids. Finally, it provides a comprehensive overview of inhibitors used to target the PI3K/AKT/mTOR pathway, including PI3K, mTOR, dual PI3K/mTOR, and AKT inhibitors. |
| Publish Date |
2025-05-20 03:37 |
| Citation |
Ni CX, Xu JJ, Pang Y, Xu JJ. Treatment strategies targeting the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway against triple-negative breast cancer. World J Clin Oncol 2025; 16(5): 104623 |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i5/104623.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i5.104623 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
